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Introduction Conclusion
• RA usually develops slowly over a 
period of weeks to months before a 
diagnosis by your Primary Care 
Provider or NP is able to be made 
(Rheumatoid Arthritis, 2014).
• Classic symptoms that will present
include: pain, swelling and stiffness 
of the peripheral joints and often 
occur in the morning, lasting longer 
than 6 weeks (Rheumatoid 
Arthritis, 2014). 
• General systemic symptoms of 
inflammation occur which include:
• Fever
• Fatigue
• Weakness
• Anorexia
• Weight loss
• Generalized aching
and stiffness 
(Richards & 
Edwards, 2014).
• Pain early on in the disease process 
occurs mainly from the pressure 
created from swelling (Huether & 
McCance, 2008).
• Later on in the disease process, 
pain occurs from abnormal 
hardening of body tissue (sclerosis) 
of the subchondral (layer of bone 
just below the cartilage in a joint) 
bone and new bone formation 
(Huether & McCance, 2008). 
• The synovial joints affected are 
usually symmetric in presentation  
and when palpated are warm and 
feel boggy with a ruddy, cyanotic 
hue and thin shiny skin 
(Rheumatoid Arthritis, 2014). 
The role of NPs in managing and 
diagnosing patients with RA are expected
to increase over the next 10-20 years
(Riley et al., 2017). Yet a survey 
conducted by Riley et al. (2017), showed 
that NP’s had a low to moderate level of 
confidence when diagnosing RA and a 
low level of confidence in managing and 
implementing treatment for patients 
with RA. This is concerning as NP’s 
working in primary care may potentially 
be the first line for diagnosis of these 
patients. 
This knowledge gap shows that 
increased training and education in RA 
could help improve NPs awareness of the 
signs and symptoms of RA, leading to an 
earlier initiation of treatment or a 
referral to a Rheumatologist (Riley et al., 
2017).
As this disease process is incurable, it 
is also important for nurses to consider 
the emotional impact that RA takes on 
their patient’s lives. RA, as outlined 
previously, causes pain, deformity,
fatigue and decreased physical function. 
These symptoms can cause emotional 
burden to patients, and it is crucial for 
nurses to assess the health-related 
quality of life (HRQL) of their patients 
when assessing treatment efficacy 
(Strand, Wright, Bergman, Tambiah & 
Taylor, 2015). 
Treatment of RA, from a patient’s 
perspective, went beyond disease 
management. Patients wanted a targeted 
approach to disease management that 
incorporated goal setting ( Strand et al., 
2015).  Patients found that setting goals 
allowed them to assess treatment 
success and made them feel more 
positive (Strand et al., 2015). Nurses 
have the ability to help patient’s set these
goals and encourage discussion with 
their APPs.
• The topic of Rheumatoid arthritis 
(RA) was chosen as this disease 
process affects up to 1% of the U.S. 
population causing disability and 
early mortality (Mayo Clinic, 2017).
• Advanced practice providers (APPs) 
are able to detect and diagnosis RA 
early on before damage to patient’s 
joints occur (Riley et al., 2017).
• As of 2017, there is an anticipated 
increase in demand over the next 
decade for health care professionals 
to be able to detect and develop 
treatment plans for patients with 
RA (Riley et al., 2017).
• Studies have shown that failing to 
recognize early or more insidious 
symptoms can hinder swift referral 
to a Rheumatologist and initiation of 
treatment (Riley et al., 2017).
• Over the past 20 years, more than 
10 new medications for RA have 
been developed and approved by 
the FDA. These new drugs have 
improved outcomes for patients 
diagnosed with RA, but can cause 
decisions about treatment plans to 
be more complex (Mayo Clinic, 
2017). 
• As a future Nurse Practitioner (NP), 
there is a high likelihood of 
encountering and diagnosing a 
patient with this disease process.
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Image 1. Shows the different stages of RA and their physical presentation
Implications for Nursing
• RA is associated with class II major
histocompatibility (MHC) antigens.
When there is a deficiency of MHC 
class II molecules, a decrease in the 
recruitment of T- helper cells is 
seen, which affects the host’s 
normal antibody response 
(Bingham, 2013).
• T-helper cell’s  responsibilities 
include the antigen- driven 
development of both B and T cells 
(Huether & McCance, 2008). 
• Because the body is not able to
properly form an attack against the 
antigen (whether foreign or self), 
the inflammatory cascade is 
initiated.
• As stated by Huether and McCance 
(2008), “The phagocytes of 
inflammation ingest the immune 
complexes and, in the process of 
doing so, release powerful enzymes 
that degrade synovial tissue and 
articular cartilage” (p. 1049).
Pathophysiology continued
• The damage occurs primarily from 
three functions:
1. Macrophages, neutrophils and other 
phagocytes of inflammation in the 
synovial fluid become activated, 
degrading the cartilage (Bingham, 
2013).
2. Cytokines stimulate synthesis of 
proinflammatory compounds. Many 
cytokines are present including 
tumor necrosis factor (TNF), 
interleukin (IL)-1, IL-6 and IL-8. 
These cytokines effects include: 
upregulation of adhesions 
molecules, activation of osteoclasts, 
induction of other inflammatory 
mediators and activation of B-cells 
among other things. These 
proinflammatory compounds cause 
chondrocytes to attack the cartilage 
(Bingham, 2013).
3. Activation of B-lymphocytes cause 
the production of more 
autoantibodies such as rheumatoid 
factor (RF) and anti-citrullinated 
peptide antibody (ACPA). While T-
lymphocytes produce enzymes that 
amplify and perpetuate the 
inflammatory response, creating a 
never ending cycle of destruction 
(Bingham, 2013). 
• Understanding the pathophysiology 
of RA will help providers create a
unique treatment plan that is
tailored to the patient. Because RA 
is an inflammatory and an immune 
mediated disease there are different 
drugs that can be utilized to prevent 
symptoms of progression of 
cartilage and bone destruction.
• The 2015 American College of 
Rheumatology developed guidelines 
that address 6 major topics for 
treatment of RA which include
1. Use of traditional disease-
modifying antirheumatic drugs 
(DMARDs), biologic DMARDs, and 
tofactinib.
2. Utilizing glucocorticoids.
3. Combination use of traditional 
and biologic DMARDs in patients 
with serious co-morbidities.
4. Using vaccines in patients before 
they start treatment of traditional 
or biologic DMARDS.
5. Screening for tuberculosis before
starting treatment.
6. Frequent laboratory monitoring 
for patients who are prescribed 
traditional DMARDs.
(Singh et al., 2015).
• DMARDs work to suppress an 
overactive immune system (Palmer 
& Miedany, 2013). This can slow or 
stop the progression of joint 
damage seen from the 
inflammatory and autoimmune 
cascades outlined in the 
pathophysiology section.
• Biologic DMARDs are suggested for 
treatment of patients with RA who 
are not responding to traditional 
DMARD therapy. Biologic DMARDs 
are TNF inhibitors which have 
shown to be effective in preventing 
joint damage and halting the 
inflammatory response (Palmer & 
Miedany, 2013).
• As stated by Palmer and Miedany
(2013), “Enhanced understanding 
of the pathophysiology of RA and 
the role of cytokines has enabled 
the development of innovative 
biological agents that target specific 
parts of the immune response” (p. 
317). 
• This is why understanding the
pathophysiology of RA is so vital to 
NPs and APPs who will develop 
treatment plans for their patients.
About RA
• RA is an immune mediated
inflammatory disease where 
your immune system attacks 
the lining of your joints causing 
swelling and inflammation 
(Barton et al., 2016). 
• RA typically affects the small 
joints in your hands and feet 
first, causing pain and stiffness 
that can develop into 
permanent damage and 
deformity if left untreated 
(Barton et al., 2016).
• Researchers have yet to 
discover the exact 
trigger/cause of RA but it is 
likely that genetics and 
environmental causes play a 
role in the development of RA 
(Barton et al., 2016). 
• There is no cure for RA, merely 
management of symptoms and 
prevention of joint 
deterioration (Barton et al., 
2016).
Signs & Symptoms
(Rheumatoid Arthritis, n.d.)  
Pathophysiology
• RA is a complex disease 
process that can be best 
characterized as an immune 
mediated inflammatory 
disease (Bingham, 2013).
• In patients with normal 
functioning immune systems, 
the body’s self-antigens are in 
a state of tolerance with the 
host’s immune system. When 
an autoimmunity response 
occurs, the patient’s immune
system begins to recognize the
host’s self-antigens as foreign 
(Huether & McCance, 2008).
• Although researchers, do not 
know the exact trigger that 
induces a RA autoimmune 
response, there is some data 
that suggests the gene HLA-
DR4 is involved (Bingham, 
2013).
• Even with some research that 
points to a genetic cause of RA, 
data has not been compiled 
that supports one specific 
trigger for the initiation of RA, 
pointing to other factors in the 
disease development (Barton 
et al., 2016).
• One of these other factors is a
bacterial or viral infection that
triggers an inflammatory 
response, or modifiable risk 
factors such as cigarette 
smoking that induces 
inflammation of the cells 
(Bingham, 2013).
Image 2. Illustrates the complex cellular process that occurs in RA
(Arend, 2001)
Rheumatoid Arthritis is an 
immune mediated inflammatory 
disease of unclear etiology. The 
disease process primarily affects 
the synovial joints of the hands and 
feet and presents in a symmetric 
presentation (Rheumatoid Arthritis, 
2014). The presence of 
autoantibodies perpetuates the 
inflammatory cascade which causes 
joint pain, swelling and if left 
untreated deformity. Studies have 
shown that early intervention is 
critical for patients receiving 
optimal outcomes (Rheumatoid 
Arthritis, 2017).
Nurse Practitioners, especially 
in the primary care setting, will 
potentially be first line access to a 
healthcare professional with 
patients who are newly diagnosed 
or have established RA (Riley et al., 
2017). Education in RA and RA
treatment is important for NPs in 
optimizing the management of RA.
Overall, RA is an insidious
disease process, that can not be 
prevented but can be managed to 
prevent long-term disability and 
improved patient outcomes.  
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